![Weekly Enforcement Report: UDTs & Diagnostic Imaging](https://www.g2intelligence.com/wp-content/uploads/2023/03/March22-2023.News_.WeeklyEnforcementReportUDTs-iStock-1800x1250-1-1080x675.jpg)
Weekly Enforcement Report: UDTs & Diagnostic Imaging
This week’s cases involved false billing allegations related to urine drug testing, as well as diagnostic imaging false claims and fraud.
This week’s cases involved false billing allegations related to urine drug testing, as well as diagnostic imaging false claims and fraud.
Recently released AACC document covers newly updated screening guidelines as well as information on surveillance and diagnosis.
Enzo recently announced that it is selling its lab division to LabCorp for $146 million in cash.
A recently released report estimates that the US market will grow at a CAGR of 4.2 percent over the next seven years.
The owners face fraud charges in two different schemes, one involving urine drug testing and one involving COVID-19 testing.
New Advisory Opinion 23-01 is similar to other arrangements the OIG has approved in the past.
In this webinar, our expert speakers will share what the end of the COVID-19 PHE will mean for clinical labs and how they can best prepare.
If Congress won’t do it, we will, the FDA says of laboratory developed test reform.
Resolution process put on hold after federal court again strikes down parts of the regulation as being unfairly weighted in favor of insurers.
Hopes are high that something will finally be done to resolve the LDTs situation this year, however that action may not come from Congress.